BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10454204
• 负责人: SUBHRA MOHAPATRA
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10454204
• 关键词: 3-Dimensional; Acute; American; Anti-Inflammatory Agents; Antineoplastic Agents; Area; Atrial Natriuretic Factor; Award; CCL20 gene; Cancer Etiology; Cardiac; Cell Therapy; Clinic; Clinical; Collaborations; Colon Carcinoma; Colorectal Cancer; Combined Modality Therapy; Common Cold Virus; Development; Diagnostic; Disease; Drug Delivery Systems; Educational process of instructing; Effectiveness; Extramural Activities; FDA approved; Face; Florida; Funding; Future; Grant; Health; Hospitals; Human; Immunocompetent; In Vitro; Inflammation; Injury; International; Iraq; Journals; Laboratory Finding; Lead; Legal patent; Literature; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of lung; Memory Loss; Mentors; Mesenchymal Stem Cells; Military Personnel; Modeling; Neoplasm Metastasis; Nerve Regeneration; Oncolytic; Organoids; Pharmaceutical Preparations; Phase; Play; Polymers; Proteins; Publications; Rattus; Relapse; Reporting; Research; Research Activity; Research Personnel; Research Support; Respiratory syncytial virus; Role; Safety; Scientist; Screening procedure; Seeds; Seminal; Services; Small Business Innovation Research Grant; Small Interfering RNA; Societies; TBI treatment; Technology; Testing; Therapeutic; Time; Training; Translating; Translational Research; Traumatic Brain Injury; Treatment Efficacy; Tumor Biology; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Veterans; Work; anti-cancer; base; cancer biomarkers; cancer diagnosis; cancer stem cell; cancer therapy; career; chemokine; colorectal cancer prevention; colorectal cancer treatment; combinatorial; controlled release; drug discovery; effective therapy; experience; graduate student; indexing; innovation; mid-career faculty; military veteran; mouse model; mutant; nano; nanofiber; nanomicelles; nanoscale; neoplasm registry; neoplastic cell; novel; novel anticancer drug; novel therapeutics; programs; receptor; scaffold; stem cell therapy; stem cells; systemic inflammatory response; targeted agent; therapeutic evaluation; three dimensional cell culture; time use; tumor; tumor growth; tumor microenvironment

This application is for a Research Career Scientist Award for Dr. Subhra Mohapatra (nominee) who is a research microbiologist at the James A. Haley VA Hospital, Tampa, FL, and an Associate Professor at the VA-affiliated academic center, the University of South Florida. Since 2007, the nominee has been contributing significantly to VA research and services via training, mentoring and collaboration with VA investigators. She is recognized nationally and internationally for her contributions to the field of tumor biology, particularly pertaining to mechanism of tumor- stroma interactions, 3D culture-based anti-cancer drug discovery, and nanoscale anti-cancer drug delivery approaches. She has contributed significantly to scientific literature including over 61 publications, which have generated ~2419 citations and a cumulative H-Index of 28 and i10-Index of 45. She also holds 12 US patents. Dr. Mohapatra has received substantial extramural research support (~$13 million) including awards from the NIH, ONR, Department of Veterans Affairs and Florida Department of Health. She also served as guest editor of the Journal of Drug Delivery and Translational Research (a journal of the Controlled Release Society) special issue entitled “NanoBio Interface: From Lab to Clinic.” She was selected for “Faces of Technology” by the Florida High Tech Corridor and was awarded the 2014 Excellence in Innovation award by the USF Office of Research and Innovation. Dr. Mohapatra has been funded with the two Merit Review Awards. She has initiated a third project for a future Merit proposal. Current research activities supported by VA Merit Review (VMR) are summarized below. VMR Project #1 (2016-2019). Investigate the potential of a novel combinatorial therapeutic approach in a rat model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by mesenchymal stem cell (MSC) therapy. VMR Project #2 (2017-2021). Investigate the potential of a novel targeted oncolytic viro-cell therapy using MSCs infected by a common cold virus, respiratory syncytial virus (RSV), for lung cancers. The project involves infecting hMSCs with wild type or mutant RSV and testing them in vitro using 3D tumoroid platform and then testing their anti-cancer potential using immunocompetent syngeneic orthotopic model of lung cancer. In addition, she serves as a co-I in a third VMR project that focuses on RSV. Project #3 (VMR project in development). Discover and investigate the potential of novel anticancer agents targeting cancer stem cells (CSCs) for the treatment of colorectal cancer (CRC). The project involves use of 3D tumoroid platform to screen for anticancer agents that will inhibit expansion of CRC-CSCs and then testing therapeutic efficacy of these agents in mouse model of CRCs. These highly innovative programs taken together are expected to lead to high impact therapies for diverse diseases for Veterans and other Americans in need. In summary, Dr. Mohapatra will be highly effective as a Research Career Scientist creating national impacts in training, mentoring, research and services at the VA.

该申请是Subhra Mohapatra博士的研究职业科学家奖 （提名人）是佛罗里达州坦帕市James A. Haley VA医院的研究微生物学家 南佛罗里达大学VA附属学术中心的副教授。自从 2007年，提名人通过培训为VA研究和服务做出了巨大贡献， 与VA调查人员进行指导和合作。她在国内和国际上得到认可 因为她对肿瘤生物学领域的贡献，特别是与肿瘤机制有关 基质相互作用，基于3D培养的抗癌药物发现和纳米级抗癌药物 交付方法。她为科学文献做出了重大贡献，包括61多个 出版物，产生了〜2419的引用，累积的H指数为28和i10索引 45岁。她还拥有12项美国专利。 Mohapatra博士接受了大量的校外研究 支持（约1300万美元），包括NIH，ONR，退伍军人事务部的奖项， 佛罗里达卫生部。她还曾担任《药物交付杂志》的客座编辑和 翻译研究（受控发行协会杂志）特刊题为“ Nanobio 界面：从实验室到诊所。“她被佛罗里达州高科技选拔为“技术面” 走廊，并被USF研究办公室授予2014年创新卓越奖 和创新。 Mohapatra博士已获得两个优异审查奖。她发起了 未来绩效提案的第三个项目。 VA功绩评论支持的当前研究活动 （VMR）总结在下面。 VMR项目＃1（2016-2019）。研究新型组合疗法的潜力 中度TBI大鼠模型中的方法，包括（i）减少炎症的治疗方法（局部 和系统性）使用纳米构造的siRNA针对最近发现的靶标CCL20和（ii） 第二种疗法可促进间充质干细胞（MSC）治疗的神经变质。 VMR项目＃2（2017-2021）。研究一种新型靶向溶瘤性毒素细胞的潜力 使用普通冷病毒感染的MSC治疗，呼吸综合病毒（RSV）用于肺 癌症。该项目涉及具有野生型或突变体RSV的感染HMSC并在体外对其进行测试 使用3D肿瘤平台，然后使用免疫能力测试其抗癌电位 肺癌的合成原位模型。此外，她在第三个VMR项目中担任Co-I 这关注RSV。 项目＃3（开发中的VMR项目）。发现并研究新颖的潜力 靶向癌细胞（CSC）治疗结直肠癌（CRC）的抗癌药。 该项目涉及使用3D肿瘤平台来筛选会抑制的抗癌剂 CRC-CSC的扩展，然后在小鼠模型中测试这些药物的治疗效率 CRC。 预计这些高度创新的计划将导致高影响力 对退伍军人和其他有需要的美国人的潜水疾病的疗法。总之，博士 作为研究职业科学家，Mohapatra将非常有效 弗吉尼亚州的培训，心理，研究和服务。